1. Home
  2. CABA vs PBHC Comparison

CABA vs PBHC Comparison

Compare CABA & PBHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CABA
  • PBHC
  • Stock Information
  • Founded
  • CABA 2017
  • PBHC 1859
  • Country
  • CABA United States
  • PBHC United States
  • Employees
  • CABA N/A
  • PBHC N/A
  • Industry
  • CABA Biotechnology: Biological Products (No Diagnostic Substances)
  • PBHC Major Banks
  • Sector
  • CABA Health Care
  • PBHC Finance
  • Exchange
  • CABA Nasdaq
  • PBHC Nasdaq
  • Market Cap
  • CABA 118.8M
  • PBHC 108.9M
  • IPO Year
  • CABA 2019
  • PBHC N/A
  • Fundamental
  • Price
  • CABA $2.58
  • PBHC $16.39
  • Analyst Decision
  • CABA Strong Buy
  • PBHC
  • Analyst Count
  • CABA 9
  • PBHC 0
  • Target Price
  • CABA $27.22
  • PBHC N/A
  • AVG Volume (30 Days)
  • CABA 1.6M
  • PBHC 9.4K
  • Earning Date
  • CABA 11-14-2024
  • PBHC 01-30-2025
  • Dividend Yield
  • CABA N/A
  • PBHC 2.40%
  • EPS Growth
  • CABA N/A
  • PBHC N/A
  • EPS
  • CABA N/A
  • PBHC 0.25
  • Revenue
  • CABA N/A
  • PBHC $35,494,000.00
  • Revenue This Year
  • CABA N/A
  • PBHC N/A
  • Revenue Next Year
  • CABA N/A
  • PBHC N/A
  • P/E Ratio
  • CABA N/A
  • PBHC $65.83
  • Revenue Growth
  • CABA N/A
  • PBHC N/A
  • 52 Week Low
  • CABA $1.76
  • PBHC $11.41
  • 52 Week High
  • CABA $26.35
  • PBHC $19.86
  • Technical
  • Relative Strength Index (RSI)
  • CABA 51.37
  • PBHC 44.31
  • Support Level
  • CABA $1.94
  • PBHC $16.38
  • Resistance Level
  • CABA $2.85
  • PBHC $16.68
  • Average True Range (ATR)
  • CABA 0.26
  • PBHC 0.40
  • MACD
  • CABA 0.07
  • PBHC -0.03
  • Stochastic Oscillator
  • CABA 72.29
  • PBHC 45.74

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

About PBHC Pathfinder Bancorp Inc. (MD)

Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.

Share on Social Networks: